Race Does Not Impact Outcome for Advanced Ovarian Cancer Patients Treated With Cisplatin/Paclitaxel An Analysis of Gynecologic Oncology Group Trials
Race Does Not Impact Outcome for Advanced Ovarian Cancer Patients Treated With Cisplatin/Paclitaxel An Analysis of Gynecologic Oncology Group Trials
复制标题
DOI：
10.1002/cncr.24482
复制
发表时间：
2009-09-15
期刊：
影响因子：
6.2
通讯作者：
Maxwell, G. Larry
中科院分区：
文献类型：
--
作者：
Farley, John H.;Tian, Chunqiao;Maxwell, G. Larry
背景技术背景：本研究的目的是确认患有卵巢癌的黑人女性和白色女性之间的结局是否存在种族差异，并确定与影响生存的辅助治疗相关的因素。方法：对97名黑人妇女和1392名白色妇女的国际妇产科联盟III/IV期卵巢癌进行了回顾性分析。所有患者均接受紫杉醇联合顺铂治疗，同时参加7项妇科肿瘤组临床试验中的1项。审查的治疗参数包括相对剂量、相对时间和相对剂量强度。比较黑人患者和白色患者的治疗参数和结局。研究结果：黑人患者和白色患者之间接受的相对剂量（0.90 vs 0.89）、相对时间（1.02 vs 0.99）或相对剂量强度（0.90 vs 0.91）没有差异。与白色女性相比，黑人女性3级和4级白细胞减少症（53%对63%; P <0.05）和胃肠道毒性（10%对19%; P <0.05）较少。体力状态>0、年龄>= 70岁、粘液组织学与未完成治疗相关（P < .001）。黑人患者的中位无进展生存期为16.2个月，白色患者为16.1个月，中位总生存期分别为37.9个月和39.7个月（P > 0.05）。结论：当他们接受类似的治疗时，黑人女性和白色女性晚期上皮性卵巢癌患者在接受妇科肿瘤组临床试验参与者类似的治疗时，临床结局没有差异。与白人相比，黑人患者在接受铂类化疗时可能会出现较轻的胃肠道毒性或白细胞减少症。Cancer 2009;115：4210-7. 2009年由美国癌症协会出版。
BACKGROUND: The objectives of this study were to confirm whether racial disparity exists with regard to outcome between black women and white women with ovarian cancer and to identify factors associated with the administration of adjuvant treatment that had an impact on survival. METHODS: A retrospective review of 97 black women and 1392 white women with International Federation of Gynecology and Obstetrics stage III/IV ovarian carcinoma was performed. All patients received paclitaxel combined with cisplatin while participating in 1 of 7 Gynecologic Oncology Group clinical trials. The treatment parameters that were reviewed included relative dose, relative time, and relative dose intensity. The treatment parameters and outcomes were compared between black patients and white patients. RESULTS: There were no differences in relative dose (0.90 vs 0.89), relative time (1.02 vs 0.99), or relative dose intensity (0.90 vs 0.91) received between black patients and white patients. Black women had less grade 3 and 4 leukopenia (53% vs 63%; P < .05) and gastrointestinal toxicity (10% vs 19%; P < .05) than white women. Performance status >0, age >= 70 years, and mucinous histology were associated with not completing treatment (P < .001). The median progression-free survival was 16.2 months for black patients and 16.1 months for white patients, and the median overall survival was 37.9 months and 39.7 months, respectively (P > .05 for all). CONCLUSIONS: When they received similar treatment, there was no difference in clinical outcome between black women and white women with advanced stage epithelial ovarian cancer when they received similar treatment as participants in Gynecologic Oncology Group clinical trials. Black patients may experience less severe gastrointestinal toxicity or leukopenia compared with whites when treated with platinum-based chemotherapy. Cancer 2009;115:4210-7. Published 2009 by the American Cancer Society.*